Market capitalization | AUD3.24b |
Enterprise Value | AUD3.33b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 369.34 |
P/S ratio (TTM) P/S ratio | 360.04 |
P/B ratio (TTM) P/B ratio | 4.49 |
Revenue growth (TTM) Revenue growth | -18.29% |
Revenue (TTM) Revenue | AUD9.01m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Mesoblast forecast:
3 Analysts have issued a Mesoblast forecast:
Jun '24 |
+/-
%
|
||
Revenue | 9.01 9.01 |
22%
22%
|
|
Gross Profit | -15 -15 |
47%
47%
|
|
EBITDA | -83 -83 |
-
|
EBIT (Operating Income) EBIT | -90 -90 |
17%
17%
|
Net Profit | -134 -134 |
10%
10%
|
In millions AUD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
Head office | Australia |
CEO | Silviu Itescu |
Employees | 73 |
Founded | 2004 |
Website | www.mesoblast.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.